Improvement of glucose levels into the normal range can occur in some people living with diabetes, either spontaneously or after medical interventions, and in some cases can persist after withdrawal of glucose-lowering pharmacotherapy. Such sustained improvement may now be occurring more often due to newer forms of treatment. However, terminology for describing this process and objective measures for defining it are not well established, and the long-term risks versus benefits of its attainment are not well understood. To update prior discussions of this issue, an international expert group was convened by the American Diabetes Association to propose nomenclature and principles for data collection and analysis, with the goal of establishing a base of information to support future clinical guidance. This group proposed "remission" as the most appropriate descriptive term, and HbA_1c <6.5% (48 mmol/mol) measured at least 3 months after cessation of glucose-lowering pharmacotherapy as the usual diagnostic criterion. The group also made suggestions for active observation of individuals experiencing a remission and discussed further questions and unmet needs regarding predictors and outcomes of remission.

一些糖尿病患者的血糖水平可能会自发地或在医疗干预后改善至正常范围，并且在某些情况下，在停止降糖药物治疗后可能会持续存在。由于新的治疗形式，这种持续的改善现在可能会更频繁地发生。然而，描述这一过程的术语和定义它的客观措施尚未建立，而且其实现的长期风险与收益也没有得到很好的理解。为了更新之前对该问题的讨论，美国糖尿病协会召集了一个国际专家组，提出数据收集和分析的术语和原则，目的是建立支持未来临床指导的信息基础。该小组提出“缓解”作为最合适的描述性术语，并在停止降糖药物治疗至少 3 个月后测量HbA _{1c <6.5% (48 mmol/mol) 作为通常的诊断标准。}该小组还提出了积极观察缓解患者的建议，并讨论了有关缓解预测因素和结果的进一步问题和未满足的需求。